Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2013

01-06-2013 | Article

Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy

Authors: J. Aranda, R. Motiejunaite, P. Silva, L. P. Aiello, A. Kazlauskas

Published in: Diabetologia | Issue 6/2013

Login to get access

Abstract

Aims/hypothesis

The realisation that targeting agents in the vitreous is an effective approach to treating patients with diabetic retinopathy (DR) has increased awareness that changes in the composition/bioactivity of the vitreous is a contributor to the pathogenesis of DR. The overall goal of this study was to test the hypothesis that the vitreous has regression activity, and that lysophosphatidic acid (LPA) contributes to such activity. LPA is a bioactive phospholipid present in many biological fluids, and has been recently appreciated for its ability to promote regression of blood vessels.

Methods

Vitreous-mediated regression was monitored on tubes organised from primary retinal endothelial cells or neovessels that sprouted from retinal explants. LPA was quantified radioenzymatically.

Results

Bovine and human vitreous promoted regression of retinal explant vessels and of tubes organised from primary retinal endothelial cells. LPA was a substantial component of this regression activity. Comparing the regression activities of vitreous from patients with different stages of DR revealed that, as patients developed proliferative diabetic retinopathy (PDR), vitreous lost its ability to promote regression, even though the amount of LPA did not change. The underlying mechanism was a PDR-vitreous-mediated insensitivity to LPA, which could be overcome pharmacologically.

Conclusions/interpretation

Our findings suggest that a decline in the responsiveness to regression factors such as LPA, which are naturally present in the vitreous, contributes to the pathogenesis of PDR.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Engerman RL, Kern TS (1995) Retinopathy in animal models of diabetes. Diabetes Metabol Rev 11:109–120CrossRef
5.
Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:143–156PubMed
6.
Gariano RF, Gardner TW (2005) Retinal angiogenesis in development and disease. Nature 438:960–966PubMedCrossRef
7.
Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef
8.
Watanabe D, Suzuma K, Matsui S et al (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782–792PubMedCrossRef
9.
10.
Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP (2010) Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol 6:494–508PubMedCrossRef
11.
Cury CE Jr, Rodrigues EB, Meyer CH, Farah ME (2009) VEGF inhibitors and vitrectomy for diabetic vitreoretinopathy. Dev Ophthalmol 44:69–81PubMedCrossRef
12.
Iacono P, Battaglia Parodi M, Bandello F (2010) Antivascular endothelial growth factor in diabetic retinopathy. Dev Ophthalmol 46:39–53PubMedCrossRef
13.
Adamis AP, Altaweel M, Bressler NM et al (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113:23–28PubMedCrossRef
14.
Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H (2008) Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 18:263–269PubMed
15.
Preis I, Langer R, Brem H, Folkman J (1977) Inhibition of neovascularization by an extract derived from vitreous. Am J Ophthalmol 84:323–328PubMed
16.
Felton SM, Brown GC, Felberg NT, Federman JL (1979) Vitreous inhibition of tumor neovascularization. Arch Ophthalmol 97:1710–1713PubMedCrossRef
17.
Lutty GA, Thompson DC, Gallup JY, Mello RJ, Patz A, Fenselau A (1983) Vitreous: an inhibitor of retinal extract-induced neovascularization. Invest Ophthalmol Vis Sci 24:52–56PubMed
18.
19.
Moolenaar WH, van Meeteren LA, Giepmans BN (2004) The ins and outs of lysophosphatidic acid signaling. Bioessays 26:870–881PubMedCrossRef
20.
Nakanaga K, Hama K, Aoki J (2010) Autotaxin—an LPA producing enzyme with diverse functions. J Biochem 148:13–24PubMedCrossRef
21.
van Meeteren LA, Ruurs P, Stortelers C et al (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26:5015–5022PubMedCrossRef
22.
Nam SW, Clair T, Kim YS et al (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61:6938–6944PubMed
23.
Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML (2000) Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19:241–247PubMedCrossRef
24.
Yeh PT, Yang CM, Huang JS et al (2008) Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 115(734–737):e731
25.
Im E, Motiejunaite R, Aranda J et al (2010) Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. Mol Cell Biol 30:2401–2410PubMedCrossRef
26.
Aranda J, Motiejunaite R, Im E, Kazlauskas A (2012) Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic Acid. Diabetes 61:1225–1233PubMedCrossRef
27.
Im E, Venkatakrishnan A, Kazlauskas A (2005) Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16:3488–3500PubMedCrossRef
28.
Im E, Kazlauskas A (2007) Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J Biol Chem 282:29122–29129PubMedCrossRef
29.
Im E, Kazlauskas A (2006) Regulating angiogenesis at the level of PtdIns-4,5-P(2). EMBO J 25:2075–2082PubMedCrossRef
30.
Saulnier-Blache JS, Girard A, Simon MF, Lafontan M, Valet P (2000) A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. J Lipid Res 41:1947–1951PubMed
31.
Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH (1993) The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 291(Pt 3):677–680PubMed
32.
Nagasaki T, Gundersen GG (1996) Depletion of lysophosphatidic acid triggers a loss of oriented detyrosinated microtubules in motile fibroblasts. J Cell Sci 109(Pt 10):2461–2469PubMed
33.
Park EY, Kazlauskas A (2012) Primary human endothelial cells secrete agents that reduce responsiveness to lysophosphatidic acid (LPA). Biosci Rep 32:393–400PubMedCrossRef
34.
Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134:348–353PubMedCrossRef
35.
36.
Mavria G, Vercoulen Y, Yeo M et al (2006) ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis. Canc Cell 9:33–44CrossRef
37.
Kowluru RA, Odenbach S (2004) Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 45:4161–4166PubMedCrossRef
38.
Groeger G, Mackey AM, Pettigrew CA, Bhatt L, Cotter TG (2009) Stress-induced activation of Nox contributes to cell survival signalling via production of hydrogen peroxide. J Neurochem 109:1544–1554PubMedCrossRef
39.
Garay RP, Hannaert P, Chiavaroli C (2005) Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 4:221–232PubMedCrossRef
40.
Kowluru RA (2003) Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818–823PubMedCrossRef
41.
Spadea L, Balestrazzi E (2001) Treatment of vascular retinopathies with Pycnogenol. Phytother Res PTR 15:219–223CrossRef
42.
Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF (1998) Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 105:2264–2270PubMedCrossRef
43.
Millen AE, Klein R, Folsom AR, Stevens J, Palta M, Mares JA (2004) Relation between intake of vitamins C and E and risk of diabetic retinopathy in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 79:865–873PubMed
44.
Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD (2008) Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells. Mol Canc Res 6:352–363CrossRef
45.
Rivera-Lopez CM, Tucker AL, Lynch KR (2008) Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11:301–310PubMedCrossRef
46.
Ausprunk DH, Falterman K, Folkman J (1978) The sequence of events in the regression of corneal capillaries. Lab Invest 38:284–294PubMed
47.
Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625–1632PubMed
Metadata
Title
Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy
Authors
J. Aranda
R. Motiejunaite
P. Silva
L. P. Aiello
A. Kazlauskas
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2884-2

Other articles of this Issue 6/2013

Diabetologia 6/2013 Go to the issue

Article

Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1α-dependent and HIF-1α-independent manner in obese mice

Short Communication

Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells

Article

Gestational diabetes, pre-pregnancy obesity and pregnancy weight gain in relation to excess fetal growth: variations by race/ethnicity

Article

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Article

Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets

Review

Evidence base in guideline generation in diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits